SHARE

According to the recently published report ‘5-Hydroxytryptamine Receptor 2B – Pipeline Review, H2 2017’; 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) – 5-Hydroxytryptamine receptor 2B (5-HT2B) or serotonin receptor 2B is a protein encoded by the HTR2B gene. It plays a role in the regulation of behavior, including impulsive behavior. It protects cardiomyocytes against apoptosis. It plays a role in the adaptation of pulmonary arteries to chronic hypoxia and vasoconstriction.

The report ‘5-Hydroxytryptamine Receptor 2B – Pipeline Review, H2 2017’ outlays comprehensive information on the 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal, Immunology, Metabolic Disorders, Oncology, Ophthalmology and Respiratory which include indications Drug Addiction, Attention Deficit Hyperactivity Disorder (ADHD), Migraine, Psychiatric Disorders, Psychosis, Pulmonary Arterial Hypertension, Schizophrenia, Systemic Sclerosis (Scleroderma), Abdominal Pain, Alzheimer’s Disease, Binge Eating Disorder, Bipolar Disorder (Manic Depression), Carcinoid Syndrome (Malignant Carcinoid Syndrome), Cirrhosis, Diarrhea, Hypertension, Idiopathic Pulmonary Fibrosis, Insomnia, Irritable Bowel Syndrome, Liver Fibrosis, Major Depressive Disorder, Memory Impairment, Neuroendocrine Tumors, Non-Alcoholic Steatohepatitis (NASH), Obesity, Ocular Hypertension, Open-Angle Glaucoma, Pervasive Developmental Disorder (PDD), Schizoaffective Disorder, Sedation and Tourette Syndrome.

Complete research report on Arterial Thrombosis- Pipeline is available at:

https://www.marketinsightsreports.com/reports/0115155422/5-hydroxytryptamine-receptor-2b-5-ht2b-or-serotonin-receptor-2b-or-htr2b-pipeline-review-h2-2017

Scope:

– The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B)
– The report reviews 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics and enlists all their major and minor projects
– The report assesses 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics

For Any queries feel free to reach us at: https://www.marketinsightsreports.com/reports/0115155422/5-hydroxytryptamine-receptor-2b-5-ht2b-or-serotonin-receptor-2b-or-htr2b-pipeline-review-h2-2017/inquiry

Reasons to buy:

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Drug Profiles : 

AAT-008, AN-3485, BBI-2000, EB-01, EB-05 , grapiprant, HPT-721, NCT-10004, pertussis [strain BPZE1] vaccine, secukinumab, SIG-1322, WOL-071007

Drug Profiles : 

BIX-01294, CM-272, EZM-8266, Small Molecules to Inhibit G9a for Breast Cancer, Small Molecules to Inhibit G9a for Oncology, TM-2115, verticillin A.

Companies Involved in Therapeutics Development are :

Domainex Ltd., Epizyme Inc.

 About Us:

MarketInsightsReports provides syndicated market research reports to industries, organizations or even individuals with an aim of helping them in their decision making process. These reports include in-depth market research studies i.e. market share analysis, industry analysis, information on products, countries, market size, trends, business research details and much more.

For more information contact at sales@marketinsightsreports.com or call us at +1 (704) 266-3234

Connect With us On: 

https://www.linkedin.com/company/13411016/

https://www.facebook.com/marketinsightsreports/

https://twitter.com/MIRresearch